Thiazolidinediones: effects on insulin resistance and the cardiovascular system
| Autor: | Cathy E. Quinn, Christopher J. Lockhart, Gary E. McVeigh, Paul Hamilton |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Pharmacology
chemistry.chemical_classification medicine.medical_specialty endocrine system diseases Adiponectin medicine.drug_class Insulin medicine.medical_treatment Adipose tissue Peroxisome proliferator-activated receptor Type 2 diabetes Biology medicine.disease Endocrinology Insulin resistance chemistry Internal medicine medicine Thiazolidinedione Rosiglitazone medicine.drug |
| Zdroj: | British Journal of Pharmacology. 153:636-645 |
| ISSN: | 0007-1188 |
| DOI: | 10.1038/sj.bjp.0707452 |
| Popis: | Thiazolidinediones (TZDs) have been used for the treatment of hyperglycaemia in type 2 diabetes for the past 10 years. They may delay the development of type 2 diabetes in individuals at high risk of developing the condition, and have been shown to have potentially beneficial effects on cardiovascular risk factors. TZDs act as agonists of peroxisome proliferator-activated receptor-γ (PPAR-γ) primarily in adipose tissue. PPAR-γ receptor activation by TZDs improves insulin sensitivity by promoting fatty acid uptake into adipose tissue, increasing production of adiponectin and reducing levels of inflammatory mediators such as tumour necrosis factor-alpha (TNF-α), plasminogen activator inhibitor-1(PAI-1) and interleukin-6 (IL-6). Clinically, TZDs have been shown to reduce measures of atherosclerosis such as carotid intima-media thickness (CIMT). However, in spite of beneficial effects on markers of cardiovascular risk, TZDs have not been definitively shown to reduce cardiovascular events in patients, and the safety of rosiglitazone in this respect has recently been called into question. Dual PPAR-α/γ agonists may offer superior treatment of insulin resistance and cardioprotection, but their safety has not yet been assured. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|